We identified 17 cases of pneumococcal bacteremia among 340 neutropenic cancer patients with bacteremia. Pneumonia was more frequent in patients with pneumococcal bacteremia than in those with bacteremia due to other organisms: 12 (71%) of 17 patients with pneumococcal bacteremia had pneumonia, whereas only 23 (7%) of 323 patients with nonpneumococcal bacteremia had pneumonia (P < .001). Eight (47%) of the 17 episodes of pneumococcal bacteremia were caused by penicillin-resistant strains (MICs ranged from 0.12 ttg/mL to 4 p,g/mL); these penicillin-resistant pneumococci showed varying degrees of diminished susceptibility to all 13-lactams studied, especially ceftazidime (MICs of this drug ranged from 1 ,u,g/mL to 64 ,u,g/mL). Imipenem was the fl-lactam agent most active against these organisms (MICs ranged from 0.03 su,g/mL to 0.25 gg/mL). Patients with penicillin-resistant pneumococcal bacteremia received inappropriate empirical antibiotic therapy more often than did patients with bacteremia due to susceptible strains (i.e., 4 (50%) of 8 patients vs. 0 of 9, respectively; P < .05). Eight (47%) of the 17 patients with pneumococcal bacteremia died. In areas where penicillin-resistant pneumococci are highly endemic, these findings should be considered in selecting empirical antibiotic therapy for neutropenic patients with cancer who are suspected of having pneumonia.
Febrile granulocytopenic patients are at great risk for developing life-threatening infections [1] . The combination of an aminoglycoside plus an antipseudomonal 0-lactam is the most common empirical treatment regimen for this patient population [2, 3] . This therapeutic approach has been shown to decrease the mortality due to septicemia caused by gram-negative bacilli [2, 3] . However, in recent years, gram-positive pathogens have been recovered at a notably increased rate from patients with cancer, and many aspects concerning the optimal management of infections due to these organisms are still controversial [4, 5] .
To date, antibiotic therapy for bacteremia due to Streptococcus pneumoniae in neutropenic patients with cancer has not deserved particular attention. However, penicillin-resistant pneumococci are being increasingly isolated worldwide [6] [7] [8] [9] [10] [11] . Furthermore, pneumococcal resistance to other antimicrobial agents is also frequent [12] [13] [14] [15] . Thus the initial empirical antibiotic therapy commonly administered to febrile neutropenic patients with cancer might be inappropriate for coverage of these resistant strains.
We report 17 cases of pneumococcal bacteremia in neutropenic patients with cancer; eight of these cases were caused by penicillin-resistant strains. We describe the clinical characteristics, antibiotic therapies, and outcomes in these cases.
Patients and Methods
Patient population. This study was carried out in a 1,000-bed teaching hospital in Barcelona, Spain, where norfloxacin is given prophylactically to patients with cancer who are neutropenic or who are likely to develop cytotoxic therapyinduced neutropenia. No other antibacterial prophylaxis is given. Ceftazidime plus amikacin was the empirical antibiotic regimen most commonly used for febrile episodes that occurred over the study period. In cases in which infection was microbiologically documented, the initial antibiotic therapy was changed, when appropriate, according to the susceptibility results.
Prospective surveillance of all cases of bacteremia is regularly performed at our institution. For the purposes of the current study, we examined data on all episodes of pneumococcal bacteremia in neutropenic patients with cancer (i.e., those with <500 granulocytes/mm) documented from 1 January 1986 through 31 December 1994. Bacteremic pneumonia was defined as the presence of an acute respiratory illness and a pulmonary infiltrate on a chest radiograph in association with positive blood cultures.
We compared the sources of bacteremic episodes caused by S. pneumoniae with those of episodes due to other organisms. We then divided all cases of pneumococcal bacteremia into two groups according to penicillin susceptibility, and we analyzed the initial empirical antimicrobial therapy and the out-come. Patients with pneumococcal bacteremia caused by resistant strains (MIC of ceftazidime, __-2 pg/mL) who were treated with this 0-lactam and amikacin were considered as having received inappropriate empirical antibiotic therapy.
Microbiological studies. Strains of S. pneumoniae were identified by standard methods. All strains were initially screened for susceptibility to antimicrobial agents by means of the disk diffusion method on Mueller-Hinton blood agar plates [16] . A 1-tig oxacillin disk was used to detect all strains with decreased susceptibility to penicillin. Strains were stored frozen at -40°C in skim milk until susceptibility testing was performed with use of the agar dilution method (performed essentially as described by Washington and Sutter [17] ). An isolate was defined as penicillin susceptible when the MIC of penicillin was <0.1 tig/mL, intermediately resistant when the MIC was between 0.1 pg/mL and 1 ktg/mL, and resistant when the MIC was .,-2 ag/mL [18] .
Statistical analysis. The x2 test or Fisher's exact test were used when appropriate for categorical variables. A P value of <.05 was considered statistically significant.
Results
During the study period, 17 episodes of pneumococcal bacteremia were identified among the 340 episodes of bacteremia in neutropenic patients with cancer. The characteristics of patients with pneumococcal bacteremia are presented in table 1. There were 11 males and 6 females; the patients' ages ranged Table 2 shows the sources of all episodes of bacteremia. Pneumonia was more frequent in patients with pneumococcal bacteremia than in patients with bacteremia due to other organisms; 12 (71%) of the 17 patients with pneumococcal bacteremia had pneumonia, whereas only 23 (7%) of 323 patients with bacteremia due to other organisms had pneumonia (P < .001). Pseudomonas aeruginosa caused 17 (74%) of the 23 cases of bacteremic pneumonia in the control group. Eight (47%) of the 17 episodes of pneumococcal bacteremia were caused by penicillin-resistant strains (MICs of penicillin ranged from 0.12 pg/mL to 4 pg/mL).
The in vitro activity of 10 antimicrobial agents against pneumococci isolated from blood cultures is shown in table 3. Penicillin-resistant pneumococci showed varying degrees of diminished susceptibility to all f3-lactams studied, especially ceftazidime. MICs of ceftazidime for these organisms ranged from 1 ,ug/mL to 64 ii,g/mL; imipenem was the most active 13-lactam agent (MICs ranged from 0.03 pg/mL to 0.25 fig/mL). All isolates were susceptible to vancomycin. Patients with penicillin-resistant pneumococcal bacteremia received inappropriate initial empirical antibiotic therapy more often than did patients with bacteremia due to susceptible strains: 4 (50%) of 8 patients with penicillin-resistant bacteremia vs. 0 of 9 patients with penicillin-susceptible bacteremia received inappropriate therapy (P < .05).
Three (75%) of the 4 patients considered as having received inappropriate empirical therapy died, while 5 (38%) of the 13 patients given appropriate therapy died. Overall, 8 (47%) of the 17 patients died. The mortality rate was 50% among patients with penicillin-resistant pneumococcal bacteremia and 44% among patients with bacteremia due to susceptible strains.
Discussion
In a recent study, the presence of an immunosuppressive underlying disorder was found to be significantly associated with invasive disease due to penicillin-resistant S. pneumoniae [19] . In addition, previous therapy with a /3-lactam and previous hospitalization, both of which are significant risk factors for the acquisition of penicillin-resistant pneumococci [20] , are frequent findings for neutropenic patients with cancer. Some previous studies that deal with pneumococcal bacteremia in patients with neoplastic disease have been published [21] [22] [23] . However, these studies mainly included patients without neutropenia and infection caused by penicillin-resistant S. pneumoniae was not documented in any of the patients.
On the other hand, our results show that about half of the episodes of pneumococcal bacteremia in neutropenic patients with cancer were due to penicillin-resistant strains. It should be noted that our study was performed in an area where penicillinresistant pneumococci are endemic [8, 24] . Nevertheless, penicillin-resistant pneumococci are being increasingly encountered throughout the world and are becoming an increasing therapeutic problem [6] [7] [8] [9] [10] [11] .
As previously reported [12] , we found that penicillin-resistant pneumococci show varying degrees of diminished susceptibility to all f3-lactam antibiotics. In particular, ceftazidime, which is frequently administered as empirical therapy for febrile episodes in neutropenic cancer patients, is one of the /3-lactams most profoundly affected by the mechanism of penicillin resistance and shows poor activity against penicillin-resistant pneumococcal strains. This observation is of great concern because of the high mortality among patients with cancer and pneumococcal bacteremia, especially when adequate empirical treatment is not given as soon as the infection is clinically suspected. In the study by Chou et al. [21] , the overall mortality rate among patients with cancer and pneumococcal bacteremia was 32%, and it reached 100% among those patients who were inadequately treated. Our study shows that patients with penicillin-resistant pneumococcal bacteremia received inappropriate empirical antibiotic therapy more often than did patients with bacteremia due to penicillin-susceptible strains. Nevertheless, our findings should be interpreted cautiously because the number of patients in the two groups described are small. It should be pointed out that three patients with pneumococcal bacteremia caused by strains resistant to ceftazidime (MIC, a 2 pg/mL) who were empirically treated with this fi-lactam antibiotic plus amikacin died of the infection.
Although peak serum levels of ceftazidime readily exceeded the MICs of the drug for most pneumococci isolated during the study period, the most important determinant of 0-lactam efficacy is the time during the dosing interval that the serum drug concentration is above the MIC for the pathogen. It is important to note that the length of time the serum concentration of ceftazidime remains above the MICs for the majority of penicillin-resistant pneumococcal strains is probably insufficient for achieving significant bactericidal activity [25] .
In our study, most neutropenic cancer patients with pneumococcal bacteremia had pneumonia. This finding concurs with those of two previously published reports that also involved patients with neoplastic disease [21, 22] ; in these reports, pneumonia was found to be the origin of pneumococcal bacteremia in 75% and 80% of the cases, respectively. Thus, at institutions where penicillin-resistant pneumococci are prevalent, the empirical antibiotic regimen used to treat neutropenic cancer patients who present with pneumonia should include drugs active against penicillin-resistant pneumococci.
We prefer to use a f3-lactam that remains active against these penicillin-resistant strains, such as imipenem, instead of vancomycin because the clinical experience with the latter agent for the treatment of pneumonia is limited. New extendedspectrum cephalosporins, such as cefpirome and cefepime, which are active against P. aeruginosa and appear to remain active against penicillin-resistant pneumococci, could be alternative agents for the empirical treatment of neutropenic patients with pneumonia.
The high mortality associated with pneumococcal bacteremia in neutropenic patients with cancer suggests the need for preventive measures such as vaccination and antibiotic prophylaxis. Vaccination with the current 23-valent pneumococcal vaccine may play a role in prophylaxis for invasive disease. However, the degree of protection afforded immunocompromised patients by vaccination remains controversial [26, 27] . On the other hand, the high rate of pneumococcal resistance to penicillin and to other drugs argues against the routine administration of antibiotic prophylaxis to prevent pneumococcal infections in patients with cancer.
In summary, in areas where penicillin-resistant pneumococci are highly endemic, empirical antibiotic regimens for febrile neutropenic patients with cancer who are suspected of having pneumonia should include drugs active against these resistant strains. However, there is no evidence that this practice will necessarily improve the outcome for such patients.
